Primary fallopian tube carcinoma - a retrospective analysis of 66 cases

Background: Primary fallopian tube carcinoma (PFTC) is a rare malignant gynecologic oncology. There was no consensus on the outcome related clinicopathological characteristics. Present study aims to determine the prognosis associate factors in PFTC. Materials and Methods: In this retrospective study, the authors identified 50 PFTC patients in Jiangsu Institute of Cancer Research and 16 cases in the Affiliated People’s Hospital of Inner Mongolia Medical College between 1988 and 2013. Disease surveillance was conducted based on the follow-up protocol of MD Anderson Cancer Center. Cox proportional hazards model and log-rank test were used to assess the associations between potential clinicpathologic characteristics and the survival durations. Results: The median progression free survival (PFS) and overall survival (OS) of PFTC were 36.9 and 62.7 months, respectively. FIGO Stage (p < 0.01, 0.01), grade (p = 0.02, 0.03), tumor residual after initial debulking surgery (p = 0.05, 0.01), nadir CA-125 (p = 0.01, 0.01) were independently related with PFS and OS. The PFS and OS of patients with Stage II PFTC were similar as those with Stage III-IV (30.7 vs 28.3 and 61.9 vs 49.2 months, respectively) but poorer than those of Stage I cases (N/A). The PFS of patients with paclitaxel-based chemotherapy was longer than those with other regime (51.3 vs 33.1 months), but not OS (62.7 vs 42.6 months). The outcome of patients underwent optimal initial cytoreduction surgery was better than those of suboptimal ones (PFS 56.4 vs 21.2 months and OS 65.3 vs 47.9 months, respectively). Conclusion: PFTC patients with FIGO Stage II disease should be regarded as advanced disease. Paclitaxel based chemotherapy was associated with longer PFS but not OS in PFTC.

Fallopian tube carcinoma; Prognosis; Nadir CA-125.

[1] Semrad N., Watring W., Fu Y.S., Hallatt J., Ryoo M., Lagasse L.: “Fallopian tube adenocarcinoma: common extraperitoneal recurrence”. Gynecol. Oncol., 1986, 24, 230.

[2] Chivukula M., Niemeier L.A., Edwards R., Nikiforova M., Mantha G., McManus K., Carter G.: “Carcinomas of Distal Fallopian Tube and Their Association with Tubal Intraepithelial Carcinoma: Do They Share a Common "Precursor" Lesion? Loss of Heterozygosity and Immunohistochemical Analysis Using PAX 2, WT-1, and P53 Markers”. ISRN Obstet. Gynecol., 2011, 2011, 858647. doi: 10.5402/2011/858647. Epub 2010 Dec 15.

[3] Nowee M.E., Dorsman J.C., Piek J.M., Kosma V.M., Hamalainen K., Verheijen R.H., et al.: “HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study”. Histopathology, 2007, 51, 666.

[4] Chung T.K., Cheung T.H., To K.F., Wong Y.F.: “Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma”. Gynecol. Obstet. Invest., 2000, 49, 47.

[5] Vicus D., Finch A., Rosen B., Fan I., Bradley L., Cass I., et al.: “Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation”. Gynecol. Oncol., 2010, 118, 155.

[6] Rabban J.T., Krasik E., Chen L.M., Powell C.B., Crawford B., Zaloudek C.J.: “Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol”. Am. J. Surg. Pathol., 2009, 33, 1878.

[7] Rabban J.T., Crawford B., Chen L.M., Powell C.B., Zaloudek C.J.: “Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingooophorectomies from women With BRCA mutations”. Am. J. Surg. Pathol., 2009, 33, 111.

[8] Tone A.A., Begley H., Sharma M., Murphy J., Rosen B, Brown T.J., et al.: “Gene expression profiles of luteal phase fallopian tubeepithelium from BRCA mutation carriers resemble high- grade serous carcinoma”. Clin. Cancer Res., 2008, 14, 4067.

[9] Chen, X., Zhang J., Zhang Z., Li H., Cheng W., Liu J.: “Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in highgrade ovarian serous carcinoma”. Human Pathol., 2013, 44, 2373. doi: 10.1016/j.humpath.2013.05.001. Epub 2013 Jul 11.

[10] Wethington S.L., Herzog T.J., Seshan V.E., Bansal N., Schiff P.B., Burke W.M., et al.: “Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer”. Cancer, 2008, 113, 3298.

[11] Chen X., Zhang J., Cheng W., Chang D.Y., Huang J., Wang X., et al.: “CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2013, 23, 815. doi: 10.1097/IGC.0b013e31828f7a24..

[12] Wang F., Ye Y., Xu X., Zhou X., Wang J., Chen X.: “CA-125- indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery”. J. Ovarian. Res., 2013, 6, 14.

[13] Chen X., Liu X., Wang J., Guo W., Sun C., Cai Z., et al.: “Functional polymorphisms of the hOGG1 gene confer risk to type 2 epithelial ovarian cancer in Chinese”. Int. J. Gynecol. Cancer, 2011, 21, 1407.

[14] Sedlis A.: “Carcinoma of the fallopian tube”. Surg. Clin. North Am., 1978, 58, 121.

[15] Moertel C.G., Hanley J.A.: “The effect of measuring error on the results of therapeutic trials in advanced cancer”. Cancer, 1976, 38, 388.

[16] Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al.: “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada”. J. Natl. Cancer Inst., 2000, 92, 205.

[17] Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al.: “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”. Eur. J. Cancer, 2009, 45, 228.

[18] Eisenhauer E., Therasse P., Bogaerts J., Schwartz L., Sargent D., Ford R., et al.: “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”. Eur. J. Cancer, 2009. 45, 228.

[19] Ou Y.C., Huang H.Y., Huang C.C., Changchien C.C., Tseng C.W., Lin H.: “Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases”. Taiwan J. Obstet. Gynecol., 2011, 50, 141.

[20] Koo Y.J., Im K.S., Kwon Y.S., Lee I.H., Kim T.J., Lim K.T., et al.: “Primary fallopian tube carcinoma: a clinicopathological analysis of a rare entity”. Int. J. Clin. Oncol., 2011, 16, 45.

[21] Rose P.G., Piver M.S., Tsukada Y.: “Fallopian tube cancer. The Roswell Park experience”. Cancer, 1990, 66, 2661.

[22] Obermair A., Taylor K.H., Janda M., Nicklin J.L., Crandon A.J., Perrin L.: “Primary fallopian tube carcinoma: the Queensland experience”. Int. J. Gynecol. Cancer, 2001, 11, 69.

[23] Nordin A.J.: “Primary carcinoma of the fallopian tube: a 20-year literature review”. Obstet. Gynecol. Surv., 1994, 49, 349. [24] Huang B.S., Chao K.C., Chang W.H., Wang P.H.: “Primary fallopian tube carcinoma”. Taiwan J. Obstet. Gynecol., 2012, 51, 143.

[25] Kurjak, A.,Kupesic S., Sparac V., Kosuta V: “Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions”. Ultrasound Obstet. Gynecol., 2000, 16, 365.

[26] Zreik, T.G., Rutherford T.J.: “Psammoma bodies in cervicovaginal smears”. Obstet. Gynecol., 2001, 97, 693.

[27] Lengyel E., Fleming S., McEwen K.A., Montag A., Temkin S.M.: “Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma”. Gynecol. Oncol., 2013, 129, 120.

[28] Gadducci A.: “Current management of fallopian tube carcinoma”. Curr. Opin. Obstet. Gynecol., 2002, 14, 27.

[29] Klein M., Graf A.H., Rosen A., Lahousen M., Hacker G.W.: “Tumor progression, histologic grading and DNA-ploidy as predictive factors of lymphogenous metastasis in primary carcinoma of the Fallopian tube”. Cancer Lett., 2002, 177, 209.

[30] Rosen A., Klein M., Lahousen M., Graf A.H., Rainer A., Vavra N.: “Primary carcinoma of the fallopian tube—a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma”. Br. J. Cancer, 1993, 68, 605.

[31] Kosary C., Trimble E.L.: “Treatment and survival for women with Fallopian tube carcinoma: a population-based study”. Gynecol. Oncol., 2002, 86, 190.

[32] Hefler L.A., Rosen A.C., Graf A.H., Lahousen M., Klein M., Leodolter S., et al.: “The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study”. Cancer, 2000, 89, 1555.

[33] Rosen A.C., Ausch C., Klein M., Graf A.H., Metzenbauer M., Philipp K., et al.: “p53 expression in fallopian tube carcinomas”. Cancer Lett., 2000, 156, 1.

[34] Cormio G.: “Experience at the Memorial Sloan-Kettering Cancer Center with paclitaxel-based combination chemotherapy following primary cytoreductive surgery in carcinoma of the fallopian tube”. Gynecol. Oncol., 2002, 84, 185.

[35] Gemignani M.L., Hensley M.L., Cohen R., Venkatraman E., Saigo P.E., Barakat R.R.: “Paclitaxel-based chemotherapy in carcinoma of the fallopian tube”. Gynecol. Oncol., 2001, 80, 16.

[36] Gadducci A., Landoni F., Sartori E., Maggino T., Zola P., Gabriele A., et al.: “Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study”. Gynecol. Oncol., 2001, 81, 150.

[37] Baekelandt M., Jorunn Nesbakken A., Kristensen G.B., Trope C.G., Abeler V.M.: “Carcinoma of the fallopian tube”. Cancer, 2000, 89, 2076.

[38] Pectasides D., Pectasides E., Papaxoinis G., Andreadis C, Papatsibas G., Fountzilas G., et al.: “Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients”. Gynecol. Oncol., 2009, 115, 97.